India’s Cipla Limited, Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Pvt Ltd., Sun Pharmaceutical Industries Ltd. and Torrent Pharmaceuticals Ltd. have announced entering into a collaboration agreement to conduct clinical trials for the investigational oral anti-viral drug molnupiravir. Under the agreement, the five companies will jointly sponsor, supervise and monitor the clinical trial of the drug indicated for the treatment of mild COVID-19 in an outpatient setting in India.
Indian Leaders Begin Unique Collaboration On Molnupiravir
Including Cipla, Dr Reddy’s, Emcure, Sun Pharma and Torrent
Major Indian pharmaceutical companies including Cipla, Dr Reddy’s, Emcure, Sun and Torrent have entered into a first-of-its-kind collaboration to jointly sponsor, supervise and monitor the clinical trial of the investigational oral anti-viral drug molnupiravir to fight against COVID-19 in India.
More from Products
• By
After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.
• By
As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.
• By
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
More from Generics Bulletin
• By
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.